A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
BCR-ABL kinase domain mutations were sequentially analyzed in a patient with chronic myeloid leukemia (CML) who exhibited repeated B-lymphoid blast crisis (CML-BC) during treatment with imatinib and dasatinib. We first identified five mutant BCR-ABL clones: Y253H, G250E, F311L, F317L and K294RGG, which was generated by two-nucleotide mutations and six-nucleotide insertion, at the third BC during the imatinib treatment, and retrospectively found that three of them (Y253H, G250E, K294RGG) were already present at the second BC. The in vitro analysis using K294RGG mutant BCR-ABL-expressing 32D cells revealed that K294RGG mutation was imatinib resistant but dasatinib sensitive. Consistent with the in vitro data, the clone with K294RGG mutation was eliminated by the dasatinib treatment in this patient. During the imatinib treatment, several mutant clones emerged and expanded, while additional mutations on the same allele were not acquired. However, after the dasatinib treatment, wild-type BCR-ABL clone disappeared and T315I or F317L mutation was acquired in G250E and Y253H mutant clones on the same allele without the emergence of each sole mutant clone. Cytogenetic and immunoglobulin heavy chain gene rearrangement analysis revealed that all mutant clones that appeared in this patient might be derived from the same CML clone.
Faculty of Pharmacy, Meijo University, Nagoya, Japan.|Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.|Department of Infectious Diseases, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya, 466-8560, Japan.
Katsuya
K
Sakai
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.|Department of Infectious Diseases, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya, 466-8560, Japan.
Yuichi
Y
Ishikawa
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.|Department of Infectious Diseases, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya, 466-8560, Japan.
Yumiko
Y
Mori
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Miki
M
Kobayashi
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Chisako
C
Iriyama
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.|Department of Infectious Diseases, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya, 466-8560, Japan.
Yukiyasu
Y
Ozawa
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.|Department of Infectious Diseases, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya, 466-8560, Japan.
Tatsuya
T
Suzuki
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yosuke
Y
Minami
Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Kazuhiro
K
Ishikawa
Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Norio
N
Kaneda
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tomoki
T
Naoe
Department of Infectious Diseases, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya, 466-8560, Japan. kiyoi@med.nagoya-u.ac.jp.
Hitoshi
H
Kiyoi
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy* / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016254:Mutagenesis, Insertional; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D017434:Protein Structure, Tertiary; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl
Eur J Haematol. 2009 Aug;83(2):90-8
19309322
Lancet Oncol. 2007 Dec;8(12):1116-1128
18054881
N Engl J Med. 2006 Dec 7;355(23):2408-17
17151364
Cancer Cell. 2009 Sep 8;16(3):232-45
19732723
Cancer Sci. 2010 Oct;101(10):2186-92
20608939
Leukemia. 2010 Jun;24(6):1105-12
20445577
Blood. 2008 Dec 1;112(12):4437-44
18716134
J Clin Oncol. 2006 Jan 20;24(3):460-6
16344315
J Clin Invest. 1992 Mar;89(3):739-46
1541668
Int J Hematol. 2009 Jun;89(5):679-88
19449194
Cell. 2003 Mar 21;112(6):831-43
12654249
Nat Rev Clin Oncol. 2009 Sep;6(9):535-43
19652654
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2076-81
18250304
Lancet. 2007 Jul 28;370(9584):342-50
17662883
Int J Hematol. 2002 Nov;76(4):349-53
12463599
Int J Hematol. 2009 Apr;89(3):332-341
19263190
Haematologica. 2009 Sep;94(9):1324-6
19734429
Blood. 2007 Oct 15;110(8):2828-37
17626839
Blood. 2004 Jun 1;103(11):4010-22
14982876